Press releases
- Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
- Innoviva to Participate in the BofA Securities Health Care Conference
- Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
- Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
Key statistics
As of last trade Innoviva Inc (HVE:BER) traded at 14.50, -5.23% below its 52-week high of 15.30, set on Jan 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.50 |
---|---|
High | 14.50 |
Low | 14.50 |
Bid | 14.50 |
Offer | 14.70 |
Previous close | 14.70 |
Average volume | 11.11 |
---|---|
Shares outstanding | 62.44m |
Free float | 61.86m |
P/E (TTM) | 7.21 |
Market cap | 986.00m USD |
EPS (TTM) | 2.19 USD |
Data delayed at least 15 minutes, as of May 24 2024 07:08 BST.
More ▼